A Phase II clinical study of AL001, in healthy human subjects.
Latest Information Update: 08 Dec 2025
At a glance
- Drugs Lithium cocrystal Alzamend Neuro (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics; Therapeutic Use
Most Recent Events
- 19 Nov 2025 According to the Alzamend Neuro media release, topline data expected in the first quarter of 2026.
- 19 Nov 2025 According to the Alzamend Neuro media release, company announced completion of the clinical portion of its first Phase II clinical study of AL001, in healthy human subjects.
- 16 Jun 2025 According to the Alzamend Neuro media release, the company announced $5 million in gross proceeds from this Financing received, The capital raised will be used to support the five Phase II clinical trials of AL001 "Lithium in Brain" Studies at Massachusetts General Hospital.